PD-1 mediates paralysis of ovarian cancer-infiltrating dendritic cells through SHP-2 dependent and independent NFkB inactivation (TUM3P.1048)
Lavakumar Karyampudi(Mayo Clinic), Keith L. Knutson(WinnMed), Jo Marie Tran Janco(Mayo Clinic), Allan B. Dietz(Mayo Clinic), Kimberly R. Kalli(Mayo Clinic), James Krempski(University of North Carolina at Chapel Hill), Karen E. Hedin(Unknown), Purushottam Lamichhane(Mayo Clinic), Marshall D. Behrens(Mayo Clinic), Doris M. Vargas(Mayo Clinic), Lynn C. Hartmann, Ellen L. Goode(Mayo Clinic in Arizona)
Cited by 0
Related Papers
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
|JNCI Journal of the National Cancer Institute|2010|716
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
|JNCI Journal of the National Cancer Institute|2015|441
Immune-Induced Epithelial to Mesenchymal Transition <i>In vivo</i> Generates Breast Cancer Stem Cells
|Cancer Research|2009|378
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer
|Nature Genetics|2013|363
Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
|The Journal of Immunology|2011|250